Urology Private Equity: Selling to an MSO or Staying Independent
Urology private equity activity has made ownership decisions more pressing for many independent groups. Investors have been drawn to the specialty’s ancillary services, aging patient population and fragmented ownership, and many urologists now receive outreach from private equity groups or the management services organizations they back.
A sale can bring liquidity and administrative support, but it also changes how the practice is governed and how physicians are paid. Staying independent preserves control but places the burden of growth, capital and succession on the partners. This guide compares the two paths. Deal structures and ownership rules vary by state, and nothing here is legal, tax or compliance advice; healthcare counsel and financial advisors should review any offer.
Why Investors Are Interested in Urology
Several features make urology groups attractive to investors:
- Revenue from multiple service lines, including imaging, pathology, radiation therapy and in-office drug administration
- Ownership stakes in surgery centers and lithotripsy partnerships
- Demand from an aging population with chronic urologic conditions
- Many small and mid-sized independent groups that can be combined into larger platforms
Those same features also create risk. Much of the ancillary revenue depends on federal self-referral rules and their exceptions. Our article on the in-office ancillary services exception explains why that area receives close attention in any transaction.
How an MSO Transaction Usually Works
Because many states restrict who can own a medical practice, investor deals in urology are often structured through a management services organization, or MSO. In a typical arrangement, the investor acquires the non-clinical assets and enters into a long-term management agreement, while the clinical practice remains owned by licensed physicians. Ownership rules vary by state and must be reviewed by counsel.
Key terms in these deals often include:
- Purchase price: frequently based on normalized earnings after a new physician compensation model is applied
- Cash and rollover equity: sellers may receive part of the price in cash and part as equity in the larger platform
- Compensation reset: physicians usually accept lower pay going forward in exchange for the upfront payment
- Employment and restrictive covenants: sellers typically commit to work for a period and accept limits on competing
- Earnouts or holdbacks: part of the price may depend on future results, and these terms deserve careful review
Understanding the Compensation Reset
The compensation reset is often the least understood part of a urology private equity deal. The investor buys a share of future earnings, so physicians generally receive less income after closing than they did as independent owners.
Senior partners close to retirement may find the trade worthwhile because they receive value for earnings they would not otherwise capture. Younger urologists may face many years of reduced pay and should weigh whether rollover equity and platform growth are likely to offset it. Our article on urology practice valuation explains how normalized earnings are calculated.
Potential Advantages of Selling
- Liquidity for partners, particularly those nearing retirement
- Access to capital for ancillary expansion, technology and recruiting
- Administrative, billing and payer contracting support
- Possible upside through rollover equity if the platform is later sold
Potential Drawbacks of Selling
- Reduced physician compensation for the long term
- Less control over staffing, purchasing, strategy and future sales
- Restrictive covenants that limit future options
- Uncertainty about the value of rollover equity
- Possible friction between senior partners who want liquidity and younger partners who bear the long-term cost
Evaluating a Urology Private Equity Offer
Letters of intent can look similar on the surface while differing in ways that matter. A headline price may include rollover equity whose future value is uncertain, holdbacks that are released only if targets are met, or adjustments for working capital and debt at closing.
Partners should ask their advisors to translate each offer into the cash they would receive at closing, the compensation they would earn afterward and the conditions attached to any deferred payments. Comparing offers on those terms, rather than on headline value alone, gives a clearer picture of what each partner is actually being offered.
Staying Independent
Independence lets partners keep control of clinical decisions, culture and earnings. It also means the group must fund its own growth and plan for partner transitions.
Independent urology groups often need financing for:
- Buying out retiring partners
- Adding or upgrading ancillary services
- Purchasing or expanding real estate
- Recruiting and bringing new partners into ownership
Partner transitions are a frequent pressure point. Our article on the urology partner buyout explains how groups may finance a retiring urologist’s interest without selling the entire practice. Larger independent groups pursuing growth or recapitalization may also explore middle market healthcare financing, subject to lender review and approval.
Questions to Ask Before Deciding
- What do the partners want over the next stage of their careers?
- How would a compensation reset affect each partner, not just the group?
- What would the group need to invest to stay competitive on its own?
- Who will lead the practice and recruit new urologists?
- How would hospitals, referral sources and staff respond to each option?
Answering these questions as a group, before an offer arrives, can make negotiations far more productive.
Preparing for Either Path
Whether a group sells or stays independent, the same preparation helps: clean financial statements for each entity, documented ancillary arrangements reviewed by counsel, clear partnership agreements and a realistic succession plan. Our article on urology practice succession covers retirement planning in more detail.
Final Thoughts
Urology private equity can offer real benefits to some groups and real costs to others. The right decision depends on the partners’ goals, ages and appetite for running the business. Understanding the compensation reset, deal terms and the financing available to independent practices can help owners compare the options on equal footing.
US Medical Funding helps urologists finance partner buyouts, expansion and growth for groups that choose to remain independent. Learn more about our urology practice financing options and our advisory and consulting services.
